Claims for Patent: 5,654,301

Summary for Patent: 5,654,301

Title:	Amino acid derivative anticonvulsant
Abstract:	The present invention relates to compounds of the formula ##STR1##
Inventor(s):	Kohn; Harold L. (Houston, TX), Watson; Darrell (Belton, TX)
Assignee:	Research Corporation Technologies, Inc. (Tucson, AZ)
Application Number:	08/003,208
Patent Claims:	1. A compound of the formula ##STR82## or the N-oxide thereof or pharmaceutically acceptable salts thereof wherein R is aryl, aryl lower alkyl, heterocyclic or heterocyclic lower alkyl, cycloalkyl, lower cycloalkyl, lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group; R.sub.1 is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, heterocyclic lower cycloalkyl, lower cylcoalkyl, lower alkyl, and R.sub.1 is unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; R.sub.1 and R.sub.3 are independently hydrogen, lower alkyl lower alkenyl, lower alkynyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, SO.sub.3.sup.31 or Z--Y wherein R.sub.2 and R.sub.3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group; Z is O, S(O).sub.a, NR.sub.4, mercaptoalkyl, alkylthio; or a chemical bond; Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic or heterocyclic lower alkyl, cycloalkyl, cycloalkyl lower alkyl and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group provided that Z is a chemical bond only when Y is halo; or ZY taken together is NR.sub.4 NR.sub.5 R.sub.7, NR.sub.4 OR.sub.5, ONR.sub.4 R.sub.7, SNR.sub.4 R.sub.7, NR.sub.4 SR.sub.7, SPR.sub.4 R.sub.5, ##STR83## R.sub.4, R.sub.5 and R.sub.6 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R.sub.4, R.sub.5 and R.sub.6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; R.sub.7 is R.sub.6, COOR.sub.8 or COR.sub.8 ; R.sub.8 is hydrogen or lower alkyl or aryl lower alkyl; n is 1-4 and a is 1-3 M is a lower alkylene chain, and A and Q are independently O or S with the provisio that at least one of A or Q is S. 2. The compound, according to claim 1 wherein A is S. 3. The compound according to claim 1 wherein A and Q are S. 4. The compound according to claim 1 wherein one of R.sub.2 and R.sub.3 is H. 5. The compound according to claim 4 wherein one of R.sub.2 and R.sub.3 is H and the other is heterocyclic. 6. The compound according to claim 5 wherein heterocyclic is furyl, pyrrolyl, pyrazoyl, epoxy, oxazolyl, imidazolyl, tetraxolyl, triazolyl, or oxadiaxoyl. 7. The compound according to claim 6 wherein heterocyclic is furyl, pyrrolyl, pyrozolyl, or pyridyl. 8. The compound according to claim 1 wherein one of R.sub.2 and R.sub.3 is H and the other is Z--Y. 9. The compound according to claim 8 wherein Z--Y is N,O-dimethylhydroxyamino, N-methylhydroxyamino N-methyoxyamino, ethylamino or methylamino or hydrazino. 10. A compound of the formula ##STR84## or the N-Oxide thereof or pharmaceutically acceptable salts thereof wherein R is aryl, aryl lower alkyl, heterocyclic or heterocyclic lower alkyl, cycloalkyl, lower cycloalkyl lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group; R.sub.1 is hydrogen or lower alkyl and R.sub.1 is unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; one of R.sub.2 and R.sub.3 is hydrogen, and the other is SO.sub.3 --, A and O are independently O or S and n is 1-4. 11. The compound according to claim 10 wherein Q and A are both O. 12. A compound of formula ##STR85## or the N-Oxide thereof or pharmaceutically acceptable salts thereof wherein R is aryl, aryl lower alkyl, heterocyclic or heterocyclic lower alkyl, cycloalkyl, lower cycloalkyl, lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group; R.sub.1 is hydrogen or lower alkyl and R.sub.1 is unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; R.sub.2 and R.sub.3 are independently hydrogen, alkyl, or Z--Y wherein R.sub.2 and R.sub.3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group; Z is S(O).sub.a, mercaptoalkyl, or alkylthio Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, heterocyclic or heterocyclic lower alkyl, cycloalkyl, cycloalkyl lower alkyl and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group provided that when Y is halo, Z is a chemical bond; or ZY taken together is NR.sub.4 ##STR86## R.sub.4, R.sub.5 and R.sub.6 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R.sub.4, R.sub.5 and R.sub.6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; n is 1-4 and a is 1-3 M is lower alkylene, and A and Q are independently O or S with the provisio that at least one of R.sub.2 and R.sub.3 is Z--Y. 13. The compound of claim 12 wherein A and Q are both oxygen. 14. A compound of the formula ##STR87## or the N-Oxide thereof or pharmaceutically acceptable salts thereof wherein R is aryl, aryl lower alkyl, heterocyclic or heterocyclic lower alkyl, cycloalkyl, lower cycloalkyl, lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group; R.sub.1 is hydrogen or lower alkyl and R.sub.1 is unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; R.sub.1 and R.sub.3 are independently hydrogen, amino, pyrrolyl, N, N-dimethylamino, morpholinyl, pyrazinyl, --NH OCH.sub.3, methylhydroxyamino, (N,O--)dimethylhydroxyamino ##STR88## or epoxy, and n is 1-4, provided that at least one of R.sub.2 and R.sub.3 is other than hydrogen. 15. The compound according to claim 14 wherein Q and A are both O. 16. The compound according to any one of claims 1-15 wherein n is 1. 17. The compound according to any one of claims 1-15 wherein R is lower arylalkyl which is unsubstituted or substituted with an electron donating group or electron withdrawing group. 18. The compound according to claim 17 wherein R is benzyl which is unsubstituted or substituted with an electron withdrawing group or electron donating group. 19. The compound according to claim 18 wherein R is unsubstituted benzyl or ##STR89## 20. The compound according to any of claims 1-15 wherein R.sub.1 is lower alkyl. 21. The compound according to claim 20 wherein R.sub.1 is methyl. 22. A compound selected from the group consisting of ethyl 2-acetamido-2-aminoacetate, ethyl 2-acetamido-2-(methylamino)acetate, ethyl 2-acetamido-2-(N,N-dimethylamino)acetate, ethyl 2-acetamido-2-(4-morpholine)acetate, ethyl 2-acetamido-2-(N-anilino)acetate, ethyl 2-acetamido-2-(N-(3-pyrazolylamino))acetate, ethyl 2-acetamido-2-(N-hydroxyamino)acetate, ethyl 2-acetamido-2-(N-(N-methylhydroxyamino))acetate, ethyl 2-acetamido-2-(N-(N,O-dimethylhydroxyamino))acetate, 2-acetamido-N-benzyl-2-aminoacetamide, 2-acetamido-N-benzyl-2-(methylamino)acetamide, 2-acetamido-N-benzyl-2-(ethylamino)acetamide, 2-acetamido-N-benzyl-2-(N-anilino)acetamide, 2-acetamido-N-benzyl-2(N-(3-pyrazolylamino))acetamide, 2-acetamido-N-benzyl-2-(N,N-dimethylamino)acetamide, 2-acetamido-N-benzyl-2-(N-hydroxyamino)acetamide, 2-acetamido-N-benzyl-2-(N-hydroxyamino)acetamide, 2-acetamido-N-benzyl-2-(N.sup.2 -phenylhydrazino)acetamide, 2-acetamido-N-benzyl-2-(N.sup.2 -benzyloxycarbonylhydrazino)acetamide, 2-acetamido-N-benzyl-2-phenoxyacetamide, 2-acetamido-N-benzyl-2-(methylmercapto)acetamide, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide, 2-acetamido-N-benzyl-2-(N-methoxyamino)acetamide, 2-acetamido-N-benzyl-2-(N-(N-methylhydroxyamino))acetamide, 2-acetamido-N-benzyl-2-(N-(N,O-dimethylhydroxyamino))acetamide, 2-acetamido-N-benzyl-2-(N-isoxazolidino)acetamide, 2-acetamido-N-benzyl-2-hydroxyacetamide, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide, 2,2-diacetamido-N-benzylacetamide, 2-acetamido-N-benzyl-2-trifluoracetamidoacetamide, 2-acetamido-N-benzyl-2-(N,N,N-trimethylammonium)acetamide tetrafluoroborate, 2-acetamido-N-benzyl-2-(ethylmercapto)acetamide-S-oxide, 2-acetamido-N-ben zyl-2-(S-ethylmercapto)acetamide-S-oxide, 2-acetamido-N-benzyl-2-(ethanesulfonyl)acetamide, 2-acetamido-N-benzyl-2-(N,N,N-trimethylammonium)acetamide tetrafluoroborate, 2-acetamido-N-benzyl-2-(1-pyrrole)acetamide, 2-acetamido-N-benzyl-2-(1-imidazole)acetamide, 2-acetamido-N-benzyl-2-(1-pyrazole)acetamide, 2-acetamido-N-benzyl-2(1-(1,2,4-triazole))acetamide, 2-acetamido-N-benzyl-2(1-tetrazole))acetamide, .alpha.-acetamido-N-benzyl-2-pyridylacetamide, .alpha.-acetamido-N-benzyl-2-pyridyl acetamide N-oxide, .alpha.-acetamido-N-benzyl-2-(S-thiophenoxy)-acetamide, .alpha.-acetamido-N-benzyl-2-(tetrahydrofuran)acetamide, methyl .alpha.-acetamido-2-methyl-2-furanacetate, .alpha.-acetamido-2-methyl-2-furanacetic acid, .alpha.-acetamido-N-benzyl-2-methyl-2-furanacetamide, .alpha.-thioacetamido-N-benzyl-2-furanacetamide, .alpha.-thioacetamido-N-benzyl-2-furanthioacetamide, .alpha.-acetamido-N-(3-pyridinylmethyl)-2-furanacetamide, .alpha.-acetamido-N-(4-pyridinylmethyl)-2-furanacetamide, .alpha.-acetamido-N-(1-oxo-3-pyridinylmethyl)-2-furanacetamide, .alpha.-acetamido-N-(1-oxo-4-pyridinylmethyl)-2-furanacetamide, R(-).alpha.-acetamido-N-(4-fluorobenzyl)-2-furanacetamide, R(-).alpha.-acetamido-N-(4-trifluoromethylbenzyl)-2-furanacetamide, methyl[acetamido(benzylcarbamoyl)methyl]carbomate, phenyl[acetamido(benzylcarbamoyl)methyl]carbomate, 1-[acetamido(benzylcarbamoyl)methyl]-3-methylurea), 1-[acetamido(benzylcarbamoyl)methyl]-3-phenylurea), 1-[acetamido(benzylcarbamoyl)methyl]-3-benzenesulfonylurea), 1-[acetamido(benzylcarbamoyl)methyl]-3-methylthiourea), 1-[acetamido(benzylcarbamoyl)methyl]-3-phenylthiourea), N-[acetamido(benzylcarbamoyl)methyl]phthalamic acid), 2-acetamido-N-benzyl-2-(N-succinimidyl)acetamide), benzyl N-[acetamido(benzylcarbamoyl)methyl]malonamate, ethyl N-[acetamido(benzylcarbamoyl)methyl]glycinate, benzyl N-[acetamido(benzylcarbamoyl)methyl]glycinate, N-[acetamido(benzylcarbomoyl)methyl]glycine, 2-acetamide-N-benzyl-2-(1-pyrrole)acetamide, 2-acetamido-N-benzyl-2-(1-pyrazole)acetamide, 2-acetamido-N-benzyl-2-(1-imidazole)acetamide, 2-acetamido-N-benzyl-2-(1-(1,2,4-triazole))acetamide, 2-acetamido-N-benzyl-2-(1-tetrazole))acetamide, .alpha.-acetamido-N-benzyl-1-(dimethylsulfamoyl)imidazole-4-acetamide, .alpha.-acetamido-N-benzyl-4-imidazole acetamide, .alpha.-acetamido-N-benzyl-2-imidazole acetamide, .alpha.-acetamido-N-benzyl-5-(tetrazole)acetamide, .alpha.-acetamido-N-benzyl-3-(1,2,4-triazole)acetamide, .alpha.-acetamido-N-benzyl-2-(carboxamide oxime)acetamide, .alpha.-acetamido-N-benzyl-2-(carboxamide oxime-(O-acetate))-acetamide, .alpha.-acetamido-N-benzyl-3-(1,2,4-oxadiazole)acetamide, .alpha.-acetamido-N-benzyl-2-(thioamide)acetamide), 2-acetamido-N-benzyl-2-vinylacetamide, 2-acetamido-N-benzyl-2-epoxyacetamide, potassium 2-acetamido-N-benzylacetamide-2-sulfonate, 2-acetamido-4-pentenic acid-N-benzylamide, .alpha.-acetamido-N-benzyl-2-(2-oxazole)-acetamide, and .alpha.-acetamido-N-benzyl-2-(2-thiazole)-acetamide. 23. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from any one of claims 1-15 and 22 and a pharmaceutical carrier therefor. 24. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim 16 and a pharmaceutical carrier therefor. 25. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim 17 and a pharmaceutical carrier therefor. 26. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from claim 18 and a pharmaceutical carrier therefor. 27. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim 19 and a pharmaceutical carrier therefor. 28. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim 20 and a pharmaceutical carrier therefor. 29. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound of claim 21 and a pharmaceutical carrier therefor. 30. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound according to any one of claims 1-15 and 22. 31. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 16. 32. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 17. 33. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 18. 34. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 19. 35. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 20. 36. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of claim 21. 37. The compound according to any one of claims 1, 10, 12 or 14 wherein n is 1 and R is lower alkyl which is unsubstituted or substituted with an electron donating group or electron withdrawing group. 38. The compound according to any one of claims 1, 10, 12 or 14 wherein n is 1; R.sub.1 is methyl and R is lower arylalkyl which is unsubstituted or substituted with an electron withdrawing group or electron donating group. 39. A compound of the formula ##STR90## or the pharmaceutically acceptable salts thereof wherein R is aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, cycloalkyl or lower cycloalkyl lower alkyl, wherein R is unsubstituted or is substituted with at least one electron withdrawing group or an electron donating group; R.sub.1 is hydrogen or lower alkyl and R.sub.1 is unsubstituted or substituted with at least one electron withdrawing group or at least one electron donating group; A and Q are both O; one of R.sub.2 and R.sub.3 is hydrogen and the other is lower alkyl which is substituted with an electron donating group or a electron withdrawing group and n is 1-4. 40. The compound according to claim 39 wherein one of R.sub.2 and R.sub.3 is hydrogen and the other is lower alkyl substituted with an electron donating group. 41. The compound according to claim 40 wherein one of R.sub.2 and R.sub.3 is alkyl substituted with an electron donating group wherein alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl or hexyl. 42. The compound according to claim 41 wherein one of R.sub.2 and R.sub.3 is methyl substituted with an electron donating group. 43. The compound according to claim 42 wherein the electron donating group is lower alkoxy. 44. The compound according to claim 43 wherein lower alkoxy is methoxy. 45. The compound according to any one of claims 39-44 wherein n is 1. 46. An anti-convulsant composition comprising an anti-convulsant effective amount of a compound from any one of claim 37-42 and a pharmaceutical carrier therefor. 47. A method of treating CNS disorders in an animal comprising administering to said animal an anti-convulsant effective amount of a compound of any one of claims 39-44.